Trial Profile
A Phase II Study Assessing SU-011248 in Previously Untreated Patients With Advanced Urothelial Cancer Ineligible for Cisplatin-Based Chemotherapy.
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Sunitinib (Primary)
- Indications Urogenital cancer
- Focus Adverse reactions; Biomarker; Therapeutic Use
- 11 May 2010 New trial record